Arterial hypertension substantially increases the risks of adverse cardiovascular and renal outcomes, including end-stage renal disease (ESRD), ischaemic cardiac and cerebrovascular events, accelerated atherosclerosis, congestive heart failure and all-cause mortality. Although most of these risks can be reduced by interventions that lower blood pressure (BP), some hypertensive individuals are treatment resistant, often owing to poor adherence or intolerance to antihypertensive therapies. The finding that combination regimens with multi ple antihypertensive drugs at optimal doses fail to achieve goal BP levels in up to 15% of hypertensive patients 1 has led to a relentless search for novel BP-lowering therapies. Four key studies published in 2015 provided new insights into the risks of uncontrolled hyper tension and the efficacies of novel approaches designed to address the unmet needs of patients with resistant hypertension (RH).
The risks of uncontrolled and difficultto-control hypertension were reinforced by the findings of a 5-year, retrospective, longitudinal cohort study of 470,386 hypertensive patients enrolled in the Kaiser Permanente health-care system 2 . In this ethnically-diverse population, 12.8% (60,327) of individuals were identified as having RH, of whom 4.9%
A key study published in 2015 provided insight into the efficacy of RDN for BP reduction in the hypertensive population. The Global Symplicity Registry (GSR) was established to address the safety and cost:benefit ratio of RDN in an uncontrolled 'real-world' population 6 . The GSR has now reported 6 month follow-up data from almost 1,000 patients with hyper tension who underwent RDN at 134 centres in five continents. Among these patients, 323 indivi duals had severe RH, defined as a pretreatment ambulatory systolic BP >135 mmHg (mean 179 ± 16 mmHg) despite treatment with at least three antihypertensive drugs. In this severe RH cohort, office systolic BP decreased by 20.3 ± 20.8 mmHg and 24 h mean systolic BP by 8.9 ± 16.9 mmHg at 6 months after RDN; 18.6% of patients achieved an office systolic BP <140 mmHg. A small reduction in the number of antihypertensive medications and low rates of complications after RDN (<1%) were also reported. These data demonstrate that RDN provides fairly safe BP reduction in patients with RH beyond that achieved using intensive pharmacological therapies.
An alternative approach to treating drugresistant hypertension was examined in a pros pective trial undertaken by the PATHWAY Studies Group of the British Hypertension Society. These researchers investigated the optimal choice of a fourth-line drug treatment for RH added to a regimen that included an angiotensinconverting-enzyme inhibitor or an angiotensin II-receptor blocker, a calcium-channel blocker and a thiazide-like diuretic. They reasoned that if RH is primarily caused by sodium retention, a diuretic would be the had controlled RH on four or more antihypertensive drugs and 7.9% had uncontrolled RH, based on a goal systolic BP of 140 mmHg and/or dia stolic BP of 90 mmHg. Individuals were followed until they experienced any outcome or until the end of the observation period. The researchers found that patients with RH had increased risks of ESRD, ischaemic cardiac events, congestive heart failure, and cerebro vascular accidents compared with those without RH (multivariable adjusted HRs of 1.32, 1.24, 1.46, 1.14 and 1.06, respectively). Importantly, patients with uncontrolled RH had similar rates of comorbidities at base line, but a 25% greater risk of ESRD and 23% greater risk of cerebrovascular accidents than those with controlled RH.
Activation of the sympathetic nervous system has a role in some forms of RH and target organ injury. In the past decade, renal denervation (RDN) has emerged as a novel, but controversial, approach to decrease BP via attenuation of sympathetic nerve activity in the renal artery. Although two large clin ical trials of RDN -Symplicity HTN-1 (REF. 3) and Symplicity HTN-2 (REF. 4 ) -reported decreases in BP with RDN and established the overall safety of the procedure, the pros pective, single-blind, randomized, shamcontrolled Symplicity HTN-3 trial, published in 2014, did not meet its efficacy end points 5 -a failure that has been partly attributed to technical confounders. Consequently, the future of RDN in the USA remains uncertain, although the procedure is used extensively in Europe for the treatment of RH. Combination therapy with optimal doses of multiple antihypertensive drugs fails to achieve blood pressure (BP) control in up to 15% of hypertensive patients. Key studies in 2015 highlighted the risks of uncontrolled hypertension and evaluated new therapeutic modalities designed to achieve satisfactory BP control in patients with treatment-resistant hypertension.
Lara Crow/NPG RDN provides fairly safe BP reduction in patients with RH most effective fourth-line therapy, whereas if the underlying pathogenic mechanisms are heterogeneous, drugs with alternative mechanisms would be equally effective and best stratified using biomarkers of sodium and/or volume status, such as plasma renin levels 7 .
In their 12-month double-blind, placebocontrolled, crossover phase IV trial, the researchers compared spironolactone, which has diuretic action based on mineralocorticoid receptor antagonism, with the α-blocker doxazosin, which reduces peripheral vascular resistance, and the β-blocker bisoprolol, which reduces renin release and cardiac output. Medication adherence was established among the participants before randomization and treatment cycles were initiated at low doses, which were doubled after 6 weeks. The intention-to-treat analysis included 314 patients, of whom 230 completed all treatment cycles. The average reduction in home systolic BP with spironolactone was superior to placebo by 8.70 mmHg, to doxazosin by 4.03 mmHg, and to bisoprolol by 4.48 mmHg. Spironolactone controlled BP in 58% of patients, and reduced BP even among those who achieved BP control with doxazosin or bisoprolol. The degree of home systolic BP reduction with spironolactone showed an inverse relationship with plasma renin levels; this drug was superior to biso prolol and doxa zosin across most of the plasma renin distribution. These findings indicate that spironolactone is a well-tolerated and effective fourth-line treatment for patients with RH, and implicate sodium retention as the predominant pathophysiological mechanism underlying RH.
In the fourth key study, Beaussier and colleagues evaluated the role of medication adherence in BP control and target organ injury among the participants of a 12-week, single-centre, prospective, randomized, open-blinded end point trial 8 . The primary study reported that among patients whose BP was not adequately controlled by a 4-week triple-therapy regimen, sequential nephron blockade (SNB) using spironolactone, furosemide and amiloride was more effective at reducing BP than sequential renin-angiotensin system (RAS) blockade using ramipril and biso prolol 9 . In their 2015 analysis, the investi gators evaluated medication adherence among the study participants using plasma irbes artan levels, urinary N-acetylserylaspartyl-lysyl-proline:creatinine ratio (a measure of ramipril effect), last medication intake >24 h before clinic visit and detailed pill counts. Their results indicated that low medication adherence was prevalent (observed among 18.3% of patients with RH) and had a differential effect on the efficacy of the drug regimens. In patients with acceptable medication adherence, but not in those with low adherence, SNB resulted in greater decreases in systolic BP (by a mean of 11.5 mmHg), pulse-wave velocity and left-ventricular mass than did sequential RAS blockade. Hence, optimizing diuretic therapy using SNB was
Key advances
• Uncontrolled resistant hypertension (RH) increases the risks of renal, cardiac and cerebrovascular complications; blood pressure (BP) control reduces these risks 2 • In a 'real-world' population of patients with RH, renal denervation provided fairly safe BP reduction beyond that achieved using intensive pharmacological therapies 6 • The diuretic spironolactone is an effective fourth-line antihypertensive drug for patients with RH, suggesting that sodium retention might be the predominant pathophysiological mechanism in these patients 7 • In patients with RH, poor medication adherence prevents effective BP control and regression of target organ damage and has differential effects on the efficacy of antihypertensive regimens 8 the most effective strategy for controlling BP and decreasing target organ damage in patients with RH. Together these key studies have advanced our understanding of the risks, prevalence and clinical significance of RH. The findings also better delineate the pathophysiology under lying RH and optimal strategies to improve BP control. Clearly, adequate BP control remains elusive and clinically consequential in a signi ficant fraction of hypertensive patients. A muti-pronged strategy invol ving behavioural and lifestyle modifications, effective broad-range drugs, and other novel approaches is likely required to decrease morbidity and mortality in the RH population.
